Cxbladder is Supreme Winner at NZ Innovators Awards

18 October 2013

Cxbladder is Supreme Winner at NZ Innovators Awards

Pacific Edge is the 2013 Supreme Winner of the NZ Innovators Award for Cxbladder, its novel gene test for the detection and management of bladder cancer.'

The citation for the Supreme Award presented in Auckland last night (17 October 2013) says: “Patient compliance is significantly enhanced with the easy-to-use, in home or in clinic urine sample system. This detection system minimises the need to go to a laboratory collection centre or wait to see the specialist at a time when the cancer can be progressing”.

Pacific Edge Chief Executive Officer David Darling says Cxbladder is a quick, cost effective, noninvasive and highly accurate cancer detection test that has significant advantages over alternative systems.

“Our focus is on developing systems for the early detection of cancers; early detection and treatment saves lives. The Supreme Award for Cxbladder is recognition of the commercialisation of the innovation, science and technology that has gone into developing this novel biomedical product and the work of the entire team of scientists, technologists and clinicians who have been involved in its development, here and overseas.”

“Pacific Edge is delighted that Cxbladder has now been launched in the US and is also available to potential bladder cancer patients in New Zealand and Australia and soon in Spain, the country with the worlds highest incidence of bladder cancer.”

ABOUT PACIFIC EDGE
Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer.

Products in development and in clinical trials are accurate and simple to use genomic and proteomic tools for the earlier detection, improved characterisation and better management of gastric, bladder, colorectal cancers and melanoma. The company has recently completed and released its first product for the detection of bladder cancer, Cxbladder, and is actively marketing the product to urologists in New Zealand, Australia and soon to be Spain and the US.

www.pacificedge.co.nz

ABOUT PACIFIC EDGE DIAGNOSTICS
Pacific Edge takes its exciting cancer detection tests to market through its wholly owned subsidiaries, Pacific Edge Diagnostics NZ Ltd and Pacific Edge Diagnostics USA Ltd, and selected commercial partners in Australia and Spain, Healthscope and Oryzon respectively.

www.pacificedgedx.com

ABOUT Cxbladder
Cxbladder is a proprietary, accurate molecular diagnostic test that enables the non-invasive detection of bladder cancer from a small volume of urine. It provides general practitioners and urologists with a quick, cost effective and accurate measure of the presence of the cancer, and provides urologists with the opportunity to reduce their reliance on the need for invasive tests such as cystoscopy. The recently published, Journal of Urology in September 2012, multi-centre international clinical study recruited 485 patients from Australia and New Zealand.

Results show that Cxbladder out-performed all of the benchmark technologies in the clinical trial and detected nearly all of the tumours of concern to a urologist; At a performance of 82% sensitivity and 85% specificity the test sees 100% of T1, 100% of T2, 100% of T3, 100% of Tis and 100% of upper urinary tract cancers as well as greater than 95% of high grade tumours.

www.cxbladder.com

ENDS

© Scoop Media